NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA,
CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE
WOULD BE UNLAWFUL.

Lille/Oslo, 24 March 2021

Reference is made to the stock exchange announcement dated 23 March 2021
regarding the preliminary results of Compagnie des Levures Lesaffre's
("Lesaffre" or the "Offeror") recommended voluntary offer to acquire all
outstanding shares in NattoPharma ASA ("NattoPharma") against a consideration in
cash of NOK 35 per share (the "Offer"), as described in the offer document dated
8 March 2021 (the "Offer Document").

Following final registration of acceptances, the acceptance level is 13,866,107
shares, representing approximately 65.91% of the issued and outstanding shares
in NattoPharma (on a fully diluted basis, excluding treasury shares) which,
together with shares already owned by the Offeror and options shares the Offeror
has agreed to acquire subject to completion of the Offer, in total amount to
16,078,112 shares, representing in total 76.43% of the issued and outstanding
shares in NattoPharma (on a fully diluted basis, excluding treasury shares).

As earlier announced, the closing conditions "Minimum Acceptance" and
"Regulatory Approval" are considered to be fulfilled. Provided that there is no
change with respect to the remaining closing conditions, Lesaffre's settlement
of the Offer will take place within two weeks from the end of the offer period,
which was on 23 March 2021.

Following settlement of the Offer, Lesaffre intends to initiate a mandatory
offer for the remaining outstanding shares of NattoPharma in accordance with
applicable laws.

Rothschild is acting as financial adviser to the Offeror and Nordea Bank Abp,
filial i Norge, is acting as receiving agent. Advokatfirmaet Thommessen AS is
acting as the Norwegian legal adviser, and Linklaters is acting as the French
legal adviser, to the Offeror in connection with the Offer.

ABG Sundal Collier ASA is acting as financial adviser and Advokatfirmaet CLP DA
is acting as Norwegian legal adviser to NattoPharma.

For further information, please contact:

NattoPharma:
NattoPharma ASA
Att: Kjetil Ramsøy
Telephone: +47 906 12 943
Email: kjetil.ramsoy@nattopharma.com

Lesaffre:
Agence Wellcom
Att: Valérie Lassale/Chloe Bencivengo
Telephone: +33(0)1 46 34 60 60
Email: lesaffre@wellcom.fr

About NattoPharma:
NattoPharma is a public limited liability company listed on Euronext Expand Oslo
and is headquartered in Oslo. NattoPharma is the world's leader in vitamin K2
research and development, and is the owner and exclusive distributer of MenaQ7®
Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending, and now the new MenaQ7® Full Spectrum, which
delivers menaquinones 6, 7, 8, and 9. The company has a multi-year research and
development program to substantiate and discover the health benefits of vitamin
K2 for applications in the marketplace for functional food and dietary
supplements.

About Lesaffre:
A key global player in fermentation for more than a century, Lesaffre, with a
2.2 billion euro turnover, and established on all continents, counts 10,700
employees and more than 85 nationalities. On the strength of this experience and
diversity, we work with customers, partners and researchers to find ever more
relevant answers to the needs of food, health, naturalness and respect for our
environment. Thus, every day, we explore and reveal the infinite potential of
microorganisms.

To nourish 10 billion people, in a healthy way, in 2050 by making the most of
our planet's resources is a major and unprecedented issue. We believe that
fermentation is one of the most promising answers to this challenge.

Important notice:
The Offer and the distribution of this announcement and other information in
connection with the Offer may be restricted by law in certain jurisdictions.
Lesaffre and the Offeror assume no responsibility in the event there is a
violation by any person of such restrictions. Persons into whose possession this
announcement or such other information should come are required to inform
themselves about and to observe any such restrictions.

THE OFFER WILL NOT BE MADE IN ANY JURISDICTION IN WHICH MAKING OF THE OFFER
WOULD NOT BE IN COMPLIANCE WITH THE LAWS OF SUCH JURISDICITON. THIS ANNOUNCEMENT
DOES NOT IN ITSELF CONSTITUTE AND OFFER. THE OFFER WILL ONLY BE MADE ON THE
BASIS OF THE OFFER DOCUMENT AND CAN ONLY BE ACCEPTED PURSUANT TO THE TERMS OF
SUCH DOCUMENT.

The Offer is subject to disclosure and procedural requirements of the Kingdom of
Norway which are different from those in the United States. In addition, the
payment and settlement procedures with respect to the Offer will comply with the
relevant Norwegian rules, which differ from United States payment and settlement
procedures.

This information is subject to the disclosure requirements of NattoPharma
pursuant to section 5 -12 of the Norwegian Securities Trading Act.